Galectin Therapeutics (GALT) EBIT Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.39% |
| Dec 31, 2025 | 15.55% |
| Sep 30, 2025 | 6.66% |
| Jun 30, 2025 | 5.39% |
| Mar 31, 2025 | -17.12% |
| Dec 31, 2024 | -19.09% |
| Sep 30, 2024 | -25.93% |
| Jun 30, 2024 | -30.18% |
| Mar 31, 2024 | -32.45% |
| Dec 31, 2023 | -26.22% |
| Sep 30, 2023 | -27.88% |
| Jun 30, 2023 | -19.09% |
| Mar 31, 2023 | -19.87% |
| Dec 31, 2022 | -34.98% |
| Sep 30, 2022 | -12.97% |
| Jun 30, 2022 | -16.44% |
| Mar 31, 2022 | -14.97% |
| Dec 31, 2021 | -10.05% |
| Sep 30, 2021 | -12.69% |
| Jun 30, 2021 | -8.18% |
| Mar 31, 2021 | 1.50% |
| Dec 31, 2020 | -10.83% |
| Sep 30, 2020 | -0.09% |
| Jun 30, 2020 | -5.55% |
| Mar 31, 2020 | 5.83% |
| Dec 31, 2019 | -6.80% |
| Sep 30, 2019 | 3.81% |
| Jun 30, 2019 | 2.20% |
| Mar 31, 2019 | 13.34% |
| Dec 31, 2018 | -1.26% |
| Sep 30, 2018 | 5.44% |
| Jun 30, 2018 | -8.10% |
| Mar 31, 2018 | -5.43% |
| Dec 31, 2017 | 0.08% |
| Sep 30, 2017 | -8.79% |
| Jun 30, 2017 | -11.09% |
| Mar 31, 2017 | -20.42% |
| Dec 31, 2016 | -6.40% |
| Sep 30, 2016 | -17.42% |
| Jun 30, 2016 | -13.08% |
| Mar 31, 2016 | -27.62% |
| Dec 31, 2015 | -29.44% |
| Sep 30, 2015 | -37.23% |
| Jun 30, 2015 | -28.10% |